Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1230731/full |
| _version_ | 1797741695549308928 |
|---|---|
| author | Ken Saijo Ken Saijo Hiroo Imai Hiroo Imai Kota Ouchi Kota Ouchi Keiju Sasaki Keiju Sasaki Yuya Yoshida Yuya Yoshida Yoshifumi Kawamura Yoshifumi Kawamura Sakura Taniguchi Sakura Taniguchi Yuki Kasahara Yuki Kasahara Keigo Komine Keigo Komine Hidekazu Shirota Hidekazu Shirota Masanobu Takahashi Masanobu Takahashi Chikashi Ishioka Chikashi Ishioka |
| author_facet | Ken Saijo Ken Saijo Hiroo Imai Hiroo Imai Kota Ouchi Kota Ouchi Keiju Sasaki Keiju Sasaki Yuya Yoshida Yuya Yoshida Yoshifumi Kawamura Yoshifumi Kawamura Sakura Taniguchi Sakura Taniguchi Yuki Kasahara Yuki Kasahara Keigo Komine Keigo Komine Hidekazu Shirota Hidekazu Shirota Masanobu Takahashi Masanobu Takahashi Chikashi Ishioka Chikashi Ishioka |
| author_sort | Ken Saijo |
| collection | DOAJ |
| description | BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.MethodsThis study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.ResultsThe 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS.ConclusionDpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC. |
| first_indexed | 2024-03-12T14:30:25Z |
| format | Article |
| id | doaj.art-89de7cd621504bb1a0fcfb1d42f525ac |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T14:30:25Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-89de7cd621504bb1a0fcfb1d42f525ac2023-08-17T13:38:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.12307311230731Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimensKen Saijo0Ken Saijo1Hiroo Imai2Hiroo Imai3Kota Ouchi4Kota Ouchi5Keiju Sasaki6Keiju Sasaki7Yuya Yoshida8Yuya Yoshida9Yoshifumi Kawamura10Yoshifumi Kawamura11Sakura Taniguchi12Sakura Taniguchi13Yuki Kasahara14Yuki Kasahara15Keigo Komine16Keigo Komine17Hidekazu Shirota18Hidekazu Shirota19Masanobu Takahashi20Masanobu Takahashi21Chikashi Ishioka22Chikashi Ishioka23Department of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanDepartment of Medical Oncology, Tohoku University Hospital, Sendai, JapanDepartment of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, JapanBackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.MethodsThis study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.ResultsThe 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS.ConclusionDpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1230731/fullimmune check point inhibitorpembrolizumabhead and neck cancerdepth of responsepredictive factor |
| spellingShingle | Ken Saijo Ken Saijo Hiroo Imai Hiroo Imai Kota Ouchi Kota Ouchi Keiju Sasaki Keiju Sasaki Yuya Yoshida Yuya Yoshida Yoshifumi Kawamura Yoshifumi Kawamura Sakura Taniguchi Sakura Taniguchi Yuki Kasahara Yuki Kasahara Keigo Komine Keigo Komine Hidekazu Shirota Hidekazu Shirota Masanobu Takahashi Masanobu Takahashi Chikashi Ishioka Chikashi Ishioka Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens Frontiers in Oncology immune check point inhibitor pembrolizumab head and neck cancer depth of response predictive factor |
| title | Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens |
| title_full | Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens |
| title_fullStr | Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens |
| title_full_unstemmed | Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens |
| title_short | Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens |
| title_sort | depth of response may predict clinical outcome in patients with recurrent metastatic head and neck cancer treated with pembrolizumab containing regimens |
| topic | immune check point inhibitor pembrolizumab head and neck cancer depth of response predictive factor |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1230731/full |
| work_keys_str_mv | AT kensaijo depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT kensaijo depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT hirooimai depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT hirooimai depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT kotaouchi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT kotaouchi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT keijusasaki depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT keijusasaki depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yuyayoshida depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yuyayoshida depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yoshifumikawamura depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yoshifumikawamura depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT sakurataniguchi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT sakurataniguchi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yukikasahara depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT yukikasahara depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT keigokomine depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT keigokomine depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT hidekazushirota depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT hidekazushirota depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT masanobutakahashi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT masanobutakahashi depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT chikashiishioka depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens AT chikashiishioka depthofresponsemaypredictclinicaloutcomeinpatientswithrecurrentmetastaticheadandneckcancertreatedwithpembrolizumabcontainingregimens |